公开(公告)号：US20240182572A1

公开(公告)日：2024-06-06

申请号：US18285664

申请日：2022-04-08

Applicant: OSE IMMUNOTHERAPEUTICS

Inventor： NICOLAS POIRIER ,  AURORE MORELLO ,  CAROLINE MARY ,  JUSTINE DURAND

IPC: C07K16/28 ,  A61K39/00 ,  A61P35/00 ,  C07K14/705

CPC classification number: C07K16/2818 ,  A61P35/00 ,  C07K14/70596 ,  A61K2039/505 ,  C07K2317/55 ,  C07K2317/565 ,  C07K2317/569 ,  C07K2317/622 ,  C07K2319/30

Abstract: The present invention relates to bifunctional molecules having a particular scaffold and their uses.

公开(公告)号：US20240181050A1

公开(公告)日：2024-06-06

申请号：US18365745

申请日：2023-08-04

Applicant: Compass Therapeutics LLC

Inventor： Piotr Bobrowicz ,  Paul Widboom ,  Michael March Schmidt ,  Jason M. Lajoie ,  Robert V. Tighe, III ,  Cheuk Lun Leung ,  Ugur Eskiocak

IPC: A61K39/395 ,  A61K35/17 ,  A61K39/00 ,  A61P35/00 ,  C07K16/28 ,  C12N15/79

CPC classification number: A61K39/39558 ,  A61K35/17 ,  A61K39/001117 ,  A61P35/00 ,  C07K16/28 ,  C07K16/2803 ,  C07K16/2818 ,  C12N15/79 ,  A61K2039/572 ,  C07K2317/33 ,  C07K2317/34 ,  C07K2317/565 ,  C07K2317/75

Abstract: The present disclosure relates to, inter alia, compounds (e.g., antibodies, or antigen-binding fragments thereof) that bind to an epitope of CD137 and agonize CD137, and to use of the compounds in methods for treating, or ameliorating one or more symptoms of, cancer.

公开(公告)号：US11999772B2

公开(公告)日：2024-06-04

申请号：US17259090

申请日：2019-07-10

Applicant: UCB BIOPHARMA SRL

Inventor： Ralph Adams ,  Terence Seward Baker ,  Xiaofeng Liu

IPC: C07K16/00 ,  C07K14/505 ,  C07K14/535 ,  C07K14/54 ,  C07K14/55 ,  C07K16/18 ,  C07K16/24 ,  C07K16/28

CPC classification number: C07K14/5443 ,  C07K14/505 ,  C07K14/535 ,  C07K14/5428 ,  C07K14/55 ,  C07K16/18 ,  C07K16/244 ,  C07K16/248 ,  C07K16/2809 ,  C07K16/2818 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/55 ,  C07K2317/56 ,  C07K2317/567 ,  C07K2317/569 ,  C07K2317/622 ,  C07K2317/76

Abstract: The present invention provides antibodies comprising a variable (V) domain and an insert polypeptide, wherein the insert polypeptide is within the framework 3 region of the V domain.

公开(公告)号：US20240174752A1

公开(公告)日：2024-05-30

申请号：US18284590

申请日：2022-04-26

Applicant: AMGEN INC.

Inventor： Li ZHANG ,  Hedieh BARKHORDARIAN ,  Ewelina ZASADZINSKA ,  Jonathan DIEP

IPC: C07K16/28 ,  C07K14/54

CPC classification number: C07K16/2818 ,  C07K14/54 ,  C07K2317/31 ,  C07K2319/30

Abstract: The present invention relates to the field of biopharmaceutical manufacturing. In particular, the invention relates to using temperature as a lever to modulate product quality during upstream operations.

公开(公告)号：US11992516B2

公开(公告)日：2024-05-28

申请号：US18045572

申请日：2022-10-11

Applicant: Altor Bioscience, LLC

Inventor： Bai Liu ,  Peter Rhode ,  Wenxin Xu ,  Hing C. Wong

IPC: A61K39/395 ,  A61K38/17 ,  A61K38/20 ,  A61K47/64 ,  A61P35/00 ,  A61K39/04 ,  C07K14/35 ,  C07K14/54 ,  C07K14/715 ,  C07K16/28 ,  C07K16/32

CPC classification number: A61K38/2086 ,  A61K38/1793 ,  A61K39/39558 ,  A61K47/6425 ,  A61P35/00 ,  A61K39/04 ,  C07K14/35 ,  C07K14/5443 ,  C07K14/7155 ,  C07K16/2818 ,  C07K16/2827 ,  C07K16/2887 ,  C07K16/2896 ,  C07K16/32 ,  C07K2317/732 ,  C07K2319/30 ,  C07K2319/32 ,  A61K38/2086 ,  A61K2300/00

Abstract: The invention features combination therapies using an IL-15-based superagonist complex and an antibody to effectively treat subjects with cancer and infectious diseases.

公开(公告)号：US20240166759A1

公开(公告)日：2024-05-23

申请号：US18473511

申请日：2023-09-25

Applicant: Angiex, Inc.

Inventor： Paul A. Jaminet ,  Shou-Ching S. Jaminet ,  Gabriel Gonzalez

IPC: C07K16/28 ,  A61K47/68 ,  A61P35/00 ,  A61K39/00

CPC classification number: C07K16/2896 ,  A61K47/68031 ,  A61K47/68033 ,  A61P35/00 ,  C07K16/2818 ,  C07K16/2827 ,  A61K2039/507 ,  C07K2317/565

Abstract: Anti-TM4SF1 antibodies, and antigen-binding fragments thereof, are described and antibody drug conjugates containing the same, and combinations of such antibodies and ADCs with an immunotherapy, such as an immunomodulatory agent.

公开(公告)号：US20240166745A1

公开(公告)日：2024-05-23

申请号：US18512607

申请日：2023-11-17

Applicant: Eli Lilly and Company

Inventor： Yaqiong LIN ,  Marta Antonina WITEK ,  Jianghuai XU

IPC: C07K16/28 ,  A61P37/06

CPC classification number: C07K16/2803 ,  A61P37/06 ,  C07K16/2818 ,  C07K2317/31 ,  C07K2317/622 ,  C07K2317/75

Abstract: The present disclosure relates to antibodies that bind to and agonize human LAG-3, and to bispecific antibodies that bind to and agonize each of human PD-1 and human LAG-3.

公开(公告)号：US20240165175A1

公开(公告)日：2024-05-23

申请号：US18279581

申请日：2022-03-08

Applicant: City of Hope

Inventor： Edward Wang ,  Er Yue

IPC: A61K35/761 ,  A61K38/19 ,  A61K38/45 ,  A61P35/00 ,  C07K16/28

CPC classification number: A61K35/761 ,  A61K38/191 ,  A61K38/193 ,  A61K38/45 ,  A61P35/00 ,  C07K16/2818 ,  C07K16/2827

Abstract: Provided herein are, inter alia, viral compositions and methods of using the same. The viral compositions comprise a virus including a nucleic acid encoding a MUC16 promoter operably linked to an essential viral gene. The compositions provided herein are contemplated to be particularly useful for treating CA-125 expressing cancers.

公开(公告)号：US11986503B2

公开(公告)日：2024-05-21

申请号：US18086594

申请日：2022-12-21

Applicant: MEMORIAL SLOAN KETTERING CANCER CENTER

Inventor： Liang Deng ,  Stewart Shuman ,  Jedd Wolchok ,  Taha Merghoub ,  Weiyi Wang ,  Peihong Dai ,  Ning Yang

IPC: A61P35/00 ,  A61K35/76 ,  A61K35/768 ,  A61K39/395 ,  A61K48/00 ,  A61P37/04 ,  C07K14/52 ,  C07K14/535 ,  C07K16/28 ,  C12N7/00 ,  C12N15/86 ,  A61K39/00

CPC classification number: A61K35/768 ,  A61K35/76 ,  A61K39/3955 ,  A61K48/00 ,  A61P35/00 ,  C07K14/521 ,  C07K14/535 ,  C07K16/2818 ,  C07K16/2827 ,  C12N15/86 ,  A61K2039/505 ,  C07K2317/76 ,  C12N2710/24121 ,  C12N2710/24132 ,  C12N2710/24133 ,  C12N2710/24143 ,  C12N2710/24161 ,  A61K39/3955 ,  A61K2300/00

Abstract: The present invention relates generally to the fields of oncology, virology and immunotherapy. More particularly, it concerns the use of poxviruses, specifically the replication competent attenuated vaccinia virus with deletion of thymidine kinase (VC-TK−) with and without the expression of human Flt3L or GM-CSF as oncolytic and immunotherapy. The foregoing poxviruses can also be used in combination with immune checkpoint blocking agents. The foregoing poxviruses can also be inactivated via Heat or UV-treatment and the inactivated virus can be used as immunotherapy either alone or in combination with immune checkpoint blocking agents.

公开(公告)号：US20240158802A1

公开(公告)日：2024-05-16

申请号：US18520449

申请日：2023-11-27

Applicant: Nutcracker Therapeutics, Inc.

Inventor： Samuel DEUTSCH ,  Daniel FRIMANNSSON ,  Nicole FAY ,  Colin McKINLAY ,  Ole HAABETH

IPC: C12N15/117 ,  A61K9/14 ,  A61K45/06 ,  A61P35/00 ,  C07K16/28

CPC classification number: C12N15/117 ,  A61K9/145 ,  A61K45/06 ,  A61P35/00 ,  C07K16/2818

Abstract: Provided herein are examples of mRNA treatment nanoparticles and methods of using them to treat a patient. An mRNA treatment nanoparticle may include one or more mRNAs encoding a tumor-specific antigen and an immunomodulatory agent; and a delivery vehicle molecule encapsulating the one or more mRNAs.